Q4 results: Biomet recon slump suggests rebound hopes premature
This article was originally published in Clinica
Executive Summary
Biomet’s modest fourth-quarter hip and knee sales growth could indicate a deceleration in the overall large joint reconstruction markets, according to analysts. Earlier this year, a run of decent results from players including Biomet itself raised hopes of a turnaround in the reconstructive market – but it now seems these may have been premature.